Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | UNG | P13051 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isophthalic Acid SCHEMBL8647102 | 0.86 | CA12 (0.62) | CA12CA1CA2CA6CA9 | |
| SCHEMBL15805914 | 0.86 | ASH1L (0.47) | CYP1A2 | |
| SCHEMBL10457004 | 0.84 | PARP1 (0.59) | HSD17B10TSHRL3MBTL1ATMTDP1 | |
| Isophthalic Acid SCHEMBL4882153 | 0.84 | CA12 (0.65) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL4614187 | 0.84 | CA12 (0.65) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL147366 | 0.83 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL22462 | 0.83 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL28756611 | 0.83 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL20500514 | 0.83 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL28462260 | 0.83 | CA12 (0.71) | CA12CA1CA2CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RES INST (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RES INST (US) | 2023-09-14 | — | — | US | disclosed |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SOUTHERN RESEARCH INSTITUTE (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SOUTHERN RESEARCH INSTITUTE (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210246110-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RESEARCH INSTITUTE | 2021-08-12 | — | — | US | disclosed |
| US-20210246110-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RESEARCH INSTITUTE | 2021-08-12 | — | — | US | disclosed |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3067053-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1815206-B1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2301536-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PCT THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1815206-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006044456-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-6043263-A | (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-28 | — | — | US | disclosed |
| EP-0941226-A1 | (2,3-DIHYDROBENZOFURANYL)-THIAZOLES AS PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998021207-A1 | (2,3-DIHYDROBENZOFURANYL)-THIAZOLES AS PHOSPHODIESTERASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-05-22 | — | — | WO | disclosed |
| US-5614520-A | 2-arylthiazole derivatives and pharmaceutical composition thereof | TEIJIN LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0513379-B1 | 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| EP-0513379-A1 | 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SMN1; SMN2, TDP2, TDP1 | CA12 4880/4885CA1 4860/4885CA2 4525/4885 |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | CA12 4708/4885CA1 4741/4885CA2 4695/4885 |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | NSUN2, UPF1, NSUN3 | CA12 4708/4885CA1 4741/4885CA2 4695/4885 |
| US-20210246110-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, TDP2, TDP1 | CA12 4880/4885CA1 4860/4885CA2 4525/4885 |
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, TDP2, TDP1 | CA12 4880/4885CA1 4860/4885CA2 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.